

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 February 2023 (09.02.2023)



(10) International Publication Number
WO 2023/014943 A1

(51) International Patent Classification:

A61K 31/437 (2006.01) C07D 471/20 (2006.01)
C07D 471/04 (2006.01) A61P 29/00 (2006.01)

(21) International Application Number:

PCT/US2022/039529

(22) International Filing Date:

05 August 2022 (05.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/229,882 05 August 2021 (05.08.2021) US

(71) Applicant: **4E THERAPEUTICS, INC.** [US/US]; 3800 N. Lamar Blvd. Ste. 200, Austin, TX 78756 (US).

(72) Inventors: **PRICE, Theodore J.**; c/o 4E Therapeutics, Inc., 3800 N. Lamar Blvd. Ste. 200, Austin, TX 78756 (US).
SAHN, James J.; c/o 4E Therapeutics, Inc., 3800 N. Lamar Blvd. Ste. 200, Austin, TX 78756 (US).

(74) Agent: **LIGON, Toby, J.** et al.; Seed Intellectual Property Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle, Washington 98104-7064 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: METHODS OF TREATING MIGRAINE WITH MNK INHIBITORS





FIG. 1



(57) Abstract: Method for treating migraines and symptoms associated with migraines comprising administering a therapeutically effective amount of a compound having activity as inhibitors of MNK are provided. One embodiment provides compounds having Structure (II) or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof, wherein R^{1a}, R^{1b}, R², X, Y, and L are as defined herein.

[Continued on next page]



WO 2023/014943 A1

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*